Ostatnio rzucił mi się w oczy temat Young Investigator Award 2020.
Niektóre tematy, które podejmują wydają się bardzo ciekawe. Może ktoś z Was słyszał o nich nieco więcej?
https://www.pcf.org/c/young-investigato ... YK8V3UlmPs
Prostate Cancer Foundation- Young investigator awards 2020
Pierwszy nieprzeczytany post • Posty: 2
• Strona 1 z 1
Prostate Cancer Foundation- Young investigator awards 2020
autor: zrebie » 21 gru 2020, 22:42
31/01/2019 - RM kręgosłupa L liczne problemy kostne Th11 i L4/5 oraz w prawym dole biodrowym najprawdopodobniej masa węzłowa wielkości 43x24x26.
08/02/2019 - USG jamy brzusznej (potwierdzenie - w podziale naczyń biodrowych prawych masa węzłowa o wym 43x27mm
18/02/2019 - TRUS - GK o obj 18cm3 (28x47x28 mm), prawy płat w całości zajęty przez lite nieco niejednorodne ognisko z drobnymi zwapnieniami, śr 26mm, prawy pęcherzyk nasienny: prawy szer 22mm, lewy 18mm.
15/02/2019 PSA 231 ng/ml , PSA wolne >50 ng/ml
20/02/2019 scyntygrafia kości liczne metastasis (8), Radiofarmaceutyk: 99nTc-MDP; Aktywność: 700MBq
21/02/2019 PSA 270 ng/ml fPSA >50ng/ml F/T>19
22/02/2019 Biopsja stercza, wynik z 27.02.2019 - T4N1M1 Gleason 8(4+4)
25/02/2019 Bikalutamid 50 Start
5/03/2019 PSA >100 ng/ml , T 4,41ng/ml
6/03/2019 I Docetaksel
14/03/2019 Reseligo 10,8 + Zomikos, PSA 283ng/ml
24/03/2019 Bikalutamid stop
27/03/2019 PSA 192 ng/ml
28/03/2019 II Docetaksel
3/04/2019 PSA 140 ng/ml; T 0,09ng/ml
17/04/2019 PSA 60,3 ng/ml; 0,08ng/ml
18/04/2019 III Docetaksel
8/05/2019 PSA 45 ng/ml; T: 0,07mg/ml
9/05/2019 IV Docetaksel
16/05/2019 II Zomikos
29/05/2019 PSA 30,2 ng/ml T: 0,18 ng/ml
30/05/2019 V Docetalsel
11/06/2019 PSA 74 ng/ml T: 0,42 ng/ml Bicalutamid start
21/06/2019 PSA 36,6 ng/ml T:0,13 ng/ml Bicalutamid stop
24.06.2019 VI Docetaksel
16/07/2019 PSA: 28,9ng/ml T:0,35 ng/ml
13/08/2019 PSA:18,9ng/ml T:0,08 ng/ml
22/08/2019 PET PSMA F-18 - liczne zmiany w kosciach; węzły zmniejszone
31/08/2019 PSA:21,12ng/ml T:0,43 ng/ml ; Bicalutamid 50 start
02/09/2019 PSA:18,2ng/ml T:0,35 ng/ml
05/09/2019 III Reseligo 10.8
17/10/2019 PSA: 6,71ng/ml T:0,16ng/ml
24/10/2019 PSA: 8,42ng/ml T:0,48ng/ml
29/10/2019 PSA: 8,61ng/ml T:0,09ng/ml
15/11/2019 PSA: 7,19ng/ml T:0,11ng/ml
21/11/2019 Reseligo 10.8
06/12/2019 PSA: 11,4ng/ml T:0,19ng/ml
11/12/2019 - PET PSMA F18 (3 aktywne zmiany)
30/12/2019 PSA: 6,53ng/ml T:0,12ng/ml
07/01/2020 PSA: 7,75ng/ml T:0,18ng/ml
13/01/2020 Scyntygrafia (pokazuje nową zmianę)
15/01/2020 PSA: 13,1ng/ml T:1ng/ml
23/01/2020 Zomikos
27/01/2020 PSA: 15,95ng/ml T:0,36ng/ml
18/02/2020 PSA: 22,5ng/ml T:0,03ng/ml
20/02/2020 Reseligo 10.8
4/03/2020 PSA: 50,8ng/ml T:0,29ng/ml
10/03/2020 TALAPRO-2 start (Enzalutamid +Talazoparib/Placebo)
24/03/2020 PSA: 15,73ng/ml T:0,27ng/ml
7/04/2020 PSA: 10,5ng/ml
02/06/2020 PSA: 9,9ng/ml
30/06/2020 PSA: 8,41ng/ml
22/07/2020 PSA: 7,26ng/ml T:0,41ng/ml
25/08/2020 PSA: 5,18ng/ml
22/09/2020 PSA: 4,63ng/ml
28/11/2020 PSA: 3.72 ng/ml
28/12/2020. PSA: 3,68 ng/ml
9/03/2021 PSA: 2,65 ng/ml (przechodzę na tryb co 2 miesiące w badaniu TALAPRO-2)
6/04/2021 PSA: 2,39 ng/ml T:0,19ng/ml
04/05/2021 PSA: 2,5 ng/ml T:0,22ng/ml
29/06/2021 PSA: 2,77 ng/ml T:0,28ng/ml
24/08/2021 PSA: 2,83 ng/ml
19/10/2021 PSA: 3,34 ng/ml
03/11/2021 PSA: 3,79 ng/ml
14/12/2021 PSA: 3,93 ng/ml
25/01/2022 PSA: 5,84 ng/ml
07/03/2022 PSA: 7,5 ng/ml
31/05/2022 PSA: 12,44 ng/ml (Rozpoczęta radioterapia 3x8Gy i 5x5,5Gy na L4i L5)
27/02/2023 PSA:34,8 ng/ml
07/03/2023 PSA:33,1 ng/ml
04/05/2023 PSA:30,25 ng/ml
27/04/2023 PSA:34,9 ng/ml
20/07/2023 PSA:32,5 ng/ml
25/08/2023 PSA:37,9 ng/ml
7/09/2023 Operacja odbarczania Th5
16/09/2023 Operacja odbarczania Th4
16/10/2023 PSA:48,8 ng/ml
20/10/2023 Radioterapia Th5 Th4 i Th8
16/12/2023 PSA:44,05 ng/ml
22/12/2023 Operacja wycięcia guza z czaszki
04/01/2023 PSA:60,1 ng/ml
14/02/2023 PSA:70 ng/ml
19/02/2023 Operacja ratunkowa odbarczania Th6-7 Th 9-11
26/02/2023 TALAPRO2 STOP
7/03/2023 Kabazytaksel Start 1 podanie
Mój wątek: viewtopic.php?t=3212
08/02/2019 - USG jamy brzusznej (potwierdzenie - w podziale naczyń biodrowych prawych masa węzłowa o wym 43x27mm
18/02/2019 - TRUS - GK o obj 18cm3 (28x47x28 mm), prawy płat w całości zajęty przez lite nieco niejednorodne ognisko z drobnymi zwapnieniami, śr 26mm, prawy pęcherzyk nasienny: prawy szer 22mm, lewy 18mm.
15/02/2019 PSA 231 ng/ml , PSA wolne >50 ng/ml
20/02/2019 scyntygrafia kości liczne metastasis (8), Radiofarmaceutyk: 99nTc-MDP; Aktywność: 700MBq
21/02/2019 PSA 270 ng/ml fPSA >50ng/ml F/T>19
22/02/2019 Biopsja stercza, wynik z 27.02.2019 - T4N1M1 Gleason 8(4+4)
25/02/2019 Bikalutamid 50 Start
5/03/2019 PSA >100 ng/ml , T 4,41ng/ml
6/03/2019 I Docetaksel
14/03/2019 Reseligo 10,8 + Zomikos, PSA 283ng/ml
24/03/2019 Bikalutamid stop
27/03/2019 PSA 192 ng/ml
28/03/2019 II Docetaksel
3/04/2019 PSA 140 ng/ml; T 0,09ng/ml
17/04/2019 PSA 60,3 ng/ml; 0,08ng/ml
18/04/2019 III Docetaksel
8/05/2019 PSA 45 ng/ml; T: 0,07mg/ml
9/05/2019 IV Docetaksel
16/05/2019 II Zomikos
29/05/2019 PSA 30,2 ng/ml T: 0,18 ng/ml
30/05/2019 V Docetalsel
11/06/2019 PSA 74 ng/ml T: 0,42 ng/ml Bicalutamid start
21/06/2019 PSA 36,6 ng/ml T:0,13 ng/ml Bicalutamid stop
24.06.2019 VI Docetaksel
16/07/2019 PSA: 28,9ng/ml T:0,35 ng/ml
13/08/2019 PSA:18,9ng/ml T:0,08 ng/ml
22/08/2019 PET PSMA F-18 - liczne zmiany w kosciach; węzły zmniejszone
31/08/2019 PSA:21,12ng/ml T:0,43 ng/ml ; Bicalutamid 50 start
02/09/2019 PSA:18,2ng/ml T:0,35 ng/ml
05/09/2019 III Reseligo 10.8
17/10/2019 PSA: 6,71ng/ml T:0,16ng/ml
24/10/2019 PSA: 8,42ng/ml T:0,48ng/ml
29/10/2019 PSA: 8,61ng/ml T:0,09ng/ml
15/11/2019 PSA: 7,19ng/ml T:0,11ng/ml
21/11/2019 Reseligo 10.8
06/12/2019 PSA: 11,4ng/ml T:0,19ng/ml
11/12/2019 - PET PSMA F18 (3 aktywne zmiany)
30/12/2019 PSA: 6,53ng/ml T:0,12ng/ml
07/01/2020 PSA: 7,75ng/ml T:0,18ng/ml
13/01/2020 Scyntygrafia (pokazuje nową zmianę)
15/01/2020 PSA: 13,1ng/ml T:1ng/ml
23/01/2020 Zomikos
27/01/2020 PSA: 15,95ng/ml T:0,36ng/ml
18/02/2020 PSA: 22,5ng/ml T:0,03ng/ml
20/02/2020 Reseligo 10.8
4/03/2020 PSA: 50,8ng/ml T:0,29ng/ml
10/03/2020 TALAPRO-2 start (Enzalutamid +Talazoparib/Placebo)
24/03/2020 PSA: 15,73ng/ml T:0,27ng/ml
7/04/2020 PSA: 10,5ng/ml
02/06/2020 PSA: 9,9ng/ml
30/06/2020 PSA: 8,41ng/ml
22/07/2020 PSA: 7,26ng/ml T:0,41ng/ml
25/08/2020 PSA: 5,18ng/ml
22/09/2020 PSA: 4,63ng/ml
28/11/2020 PSA: 3.72 ng/ml
28/12/2020. PSA: 3,68 ng/ml
9/03/2021 PSA: 2,65 ng/ml (przechodzę na tryb co 2 miesiące w badaniu TALAPRO-2)
6/04/2021 PSA: 2,39 ng/ml T:0,19ng/ml
04/05/2021 PSA: 2,5 ng/ml T:0,22ng/ml
29/06/2021 PSA: 2,77 ng/ml T:0,28ng/ml
24/08/2021 PSA: 2,83 ng/ml
19/10/2021 PSA: 3,34 ng/ml
03/11/2021 PSA: 3,79 ng/ml
14/12/2021 PSA: 3,93 ng/ml
25/01/2022 PSA: 5,84 ng/ml
07/03/2022 PSA: 7,5 ng/ml
31/05/2022 PSA: 12,44 ng/ml (Rozpoczęta radioterapia 3x8Gy i 5x5,5Gy na L4i L5)
27/02/2023 PSA:34,8 ng/ml
07/03/2023 PSA:33,1 ng/ml
04/05/2023 PSA:30,25 ng/ml
27/04/2023 PSA:34,9 ng/ml
20/07/2023 PSA:32,5 ng/ml
25/08/2023 PSA:37,9 ng/ml
7/09/2023 Operacja odbarczania Th5
16/09/2023 Operacja odbarczania Th4
16/10/2023 PSA:48,8 ng/ml
20/10/2023 Radioterapia Th5 Th4 i Th8
16/12/2023 PSA:44,05 ng/ml
22/12/2023 Operacja wycięcia guza z czaszki
04/01/2023 PSA:60,1 ng/ml
14/02/2023 PSA:70 ng/ml
19/02/2023 Operacja ratunkowa odbarczania Th6-7 Th 9-11
26/02/2023 TALAPRO2 STOP
7/03/2023 Kabazytaksel Start 1 podanie
Mój wątek: viewtopic.php?t=3212
- zrebie
- Posty: 157
- Rejestracja: 27 lut 2019, 11:09
- Blog: Wyświetl blog (0)
Re: Prostate Cancer Foundation- Young investigator awards 20
autor: zosia bluszcz » 22 gru 2020, 00:30
Poniżej lista nagrodzonych przez Prostate Cancer Foundation badaczy i tematów badan za rok 2020 z linku podanego prze Źrebie (ominęłam badania specyficznie dotyczące raka prostaty u Afro-Amerykanów).
Tematy badań są interesujące, ale co i kiedy z nich realnie wyniknie dla pacjentów z CaP trudno w tej chwili powiedzieć. Zresztą większość z zaprezentowanych tematów w podsumowaniu zawiera słowa could & may, bo jest oczywiste, że dopiero pozytywne wyniki badań klinicznych (które ktoś będzie musiał sfinansować) umożliwią ewentualne zastosowanie proponowanych przez badaczy procedur czy testów w diagnostyce/leczeniu raka prostaty.
Investigating Novel Epigenetic Drivers of Bone Metastasis and Treatment Response in Metastatic Castration-Resistant Prostate Cancer
What this means to patients: Dr. Arriaga is studying the biology of prostate cancer bone metastasis, specifically the role of ATAD2, and a driver of bone metastasis and possible new treatment target. This may result in an effective new therapeutic strategy to prevent or treat metastatic prostate cancer.
Micro-Ultrasound and MRI Investigation of Human Prostate Cancer
What this means to patients: Dr. Brisbane is studying the potential for a novel imaging technology, micro-ultrasound, for detection and prognosis of prostate cancer. This may lead to better optimization of treatment selection and improved outcomes for patients.
Validating a PET Imaging Biomarker for Targeting Fibroblast Activation Protein in Prostate Cancer Stroma
What this means to patients: Dr. Calais is developing a novel prostate cancer imaging agent, FAPi-PET, which looks at tumor stroma instead of the tumor cells themselves. This project will determine the performance of FAPi-PET for prostate cancer detection and prognosis, and will be used to launch the development of new FAP-targeting precision medicines
Understanding the Role of Androgen Signaling in Facilitating Immune Evasion in Advanced Prostate Cancer
What this means to patients: Dr. Chesner is investigating whether levels of MHC, which are proteins required for anti-tumor immune responses, are suppressed in prostate cancer via AR. This project will also reveal whether AR-targeted therapy may synergize with immunotherapy and could lead to new therapeutic strategies for patients with prostate cancer.
Discovering Precision Oncology Approaches for CDK12-Deficient Prostate Cancer
What this means to patients: Dr. Chou is studying the biology of CDK12-mutated prostate cancers, a distinct molecular subtype of prostate cancer, which is seen in ~7% of mCRPC patients. This project will identify the impact of CDK12 mutations on the AR pathway, and identify new treatment targets for patients with this more aggressive subtype of prostate cancer.
Defining the Role of Natural Killer Cells in the Radiotherapy Treatment Response of Metastatic Prostate Cancer
What this means to patients: Dr. Foroutan is studying NK immune cell biology in patients treated with LuPSMA combined with checkpoint immunotherapy or PARP-inhibitors. This project may help to identify NK cell biomarkers that are predictive of response to therapy and potential targets that could be used for NK cell immunotherapy to increase the efficacy of therapy outcome in patients with poor clinical outcome.
A Multi-Center Study to Assess the Impact of MRI for Detection of Aggressive Prostate Cancer in Men on Active Surveillance
What this means to patients: Dr. Giganti is developing a new standardized mpMRI method (“PRECISE score”) for more accurate risk assessment and monitoring of disease progression in prostate cancer patients undergoing active surveillance. This will lead to reduced global incidence of advanced and potentially lethal prostate cancer.
Exploration of Metabolomics for the Prevention of Lethal Prostate Cancer
What this means to patients: Dr. Graff is profiling metabolite alterations in prostate cancer patients in order to develop a biomarker that can be used to identify which patients are at highest risk for developing lethal disease. This will enable more informed treatment decisions for patients and may be leveraged for efforts to develop new targeted treatments.
Investigating the Pathological Role of AZI1 RNA in TMPRSS2-ERG Gene Fusion Formation
What this means to patients: Dr. Gupta has discovered an RNA that may induce the gene fusions that drive the development of 50% of prostate cancer cases. This project will validate this phenomenon and describe its mechanisms, which may lead to new strategies to prevent the initiation of prostate cancer.
Improving Outcomes for PARP Inhibition Treatment in Men with Lethal BRCA2 Mutant Prostate Cancer by Targeting the Tumor Microenvironment
What this means to patients: Dr. Hepburn is studying mechanisms of PARP inhibitor resistance in BRCA2-mutated prostate cancer and identifying new combination treatment strategies that will lead to improved outcomes for these patients.
Developing a Novel ctDNA-Based Approach to Patient Risk Stratification and Treatment Selection in mCRPC: A Large Population-Based Cohort Study
What this means to patients: Dr. Khalaf is developing non-invasive, blood-based biomarker tests that evaluate circulating tumor DNA levels and tumor mutations to predict outcomes and identify optimal treatment strategies for patients. This project will greatly accelerate precision medicine and improve outcomes for patients with prostate cancer.
Using CDK4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy
What this means to patients: Dr. Koshkin will test the efficacy of a novel treatment strategy that uses a CDK4/6-inhibitor followed by PSMA-targeted radioligand therapy in patients with mCRPC, which may improve outcomes and treatment options in patients with advanced prostate cancer.
Targeting Fc Gamma Receptors with Stereotactic Radiation to Reprogram Myeloid-Derived Immune Cells in the Prostate Tumor Microenvironment
What this means to patients: Radiation therapy can sometimes activate anti-tumor immune responses, and strategies that boost this effect will improve treatment efficacy and outcomes for patients. Dr. Marciscano will explore whether targeting FcɣRs on myeloid cell is an effective strategy to enhance the immune response to SBRT in men with prostate cancer.
Uncovering Lineage Plasticity in the Context of Specific Genomic Alterations in High Risk Prostate Cancer
What this means to patients: Dr. Nappi is investigating mechanisms of treatment resistance and response in patients with high-risk localized prostate cancer in a neoadjuvant precision medicine clinical trial. This study will uncover mechanisms associated with lineage plasticity and early signatures of treatment resistance, enabling refinement of future precision medicine approaches.
Biomarker-Based Approaches to Predict Fracture Risk among Men with Metastatic Hormone-Sensitive Prostate Cancer
What this means to patients: Dr. Parikh is developing new clinical biomarker tests that can identify which patients undergoing hormonal therapy are at risk for developing bone fractures, and should be prescribed early bone maintenance therapies. This will significantly improve quality-of-life for patients with advanced prostate cancer, starting with the Veteran population.
Interrupting the Aberrant Cancer Development Sequence in Prostate Cancer Progression
What this means to patients: Dr. Park will identify the essential genetic/molecular switches that control progression of prostate cancer into NEPC and enable NEPC to grow rapidly, which may represent new therapeutic targets for preventing or reversing NEPC development.
Metabolic Adaptations to Androgen Receptor Blockade and the Prostate Cancer Transcriptome.
What this means to patients: Dr. Paschalis is studying a novel environmental metabolic sensing pathway that may drive CRPC by altering expression levels of AR-V7. This project will determine the mechanisms of this pathway and validate the potential for targeting this pathway as a new treatment strategy in CRPC.
Molecular Pathology-Artificial Intelligence Approach to Therapy Response Prediction for Castration Resistant Prostate Cancer
What this means to patients: Dr. Antonio Rodriguez-Calero is developing a new artificial intelligence-based classification system for mCRPC based on molecular, pathology, and clinical data that will improve precision medicine treatment selection for patients with advanced prostate cancer.
Phase II Biomarker Study of Advanced Diffusion MRI in High-Risk, Localized Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy
What this means to patients: Dr. Seibert is developing a new MRI scan technique that will help to identify patients with high-risk localized prostate cancer who will vs. will not be cured by ADT + radiation therapy. This will enable clinicians to identify which patients should have additional therapy before waiting for recurrence to become apparent, and will lead to improved outcomes for patients with high-risk prostate cancer.
Integrated Single-Cell Analysis of Mechanisms of Therapeutic Resistance in Prostate Cancer Patients
What this means to patients: Dr. Tewari is investigating molecular mechanisms and biomarkers of response vs. resistance to intense anti-androgen neoadjuvant therapy, radiopharmaceuticals, and other treatments. This will result in improved selection of patients who will benefit from these treatments and potentially inform drug development efforts to improve the chance of cure for patients with prostate cancer.
Biochemical, Structural and Molecular Dissection of Androgen Receptor Transcriptional Activity
What this means to patients: Dr. Wasmuth will identify the precise regions of the AR that regulate its oncogenic activities and reveal novel strategies for developing new drugs to target this critical prostate cancer driver.
Studying the Mechanisms of Lineage Plasticity in Prostate Cancer
What this means to patients: Dr. Zaidi is studying the biology of lineage plasticity, a mechanism that drives development of an aggressive form of CRPC. These findings will uncover new therapeutic targets for drug development for this currently lethal prostate cancer subtype.
Investigating Cell of Origin and Molecular Mechanisms of Lineage Plasticity in Neuroendocrine Prostate Cancer
What this means to patients: Dr. Zhao is investigating the molecular drivers and role of neutrophils in lineage plasticity, a major form of treatment resistance in patients with mCRPC. This will lead to new understandings and identify promising new therapeutic strategies for patients with this highly aggressive form of prostate cancer.
Tematy badań są interesujące, ale co i kiedy z nich realnie wyniknie dla pacjentów z CaP trudno w tej chwili powiedzieć. Zresztą większość z zaprezentowanych tematów w podsumowaniu zawiera słowa could & may, bo jest oczywiste, że dopiero pozytywne wyniki badań klinicznych (które ktoś będzie musiał sfinansować) umożliwią ewentualne zastosowanie proponowanych przez badaczy procedur czy testów w diagnostyce/leczeniu raka prostaty.
Investigating Novel Epigenetic Drivers of Bone Metastasis and Treatment Response in Metastatic Castration-Resistant Prostate Cancer
What this means to patients: Dr. Arriaga is studying the biology of prostate cancer bone metastasis, specifically the role of ATAD2, and a driver of bone metastasis and possible new treatment target. This may result in an effective new therapeutic strategy to prevent or treat metastatic prostate cancer.
Micro-Ultrasound and MRI Investigation of Human Prostate Cancer
What this means to patients: Dr. Brisbane is studying the potential for a novel imaging technology, micro-ultrasound, for detection and prognosis of prostate cancer. This may lead to better optimization of treatment selection and improved outcomes for patients.
Validating a PET Imaging Biomarker for Targeting Fibroblast Activation Protein in Prostate Cancer Stroma
What this means to patients: Dr. Calais is developing a novel prostate cancer imaging agent, FAPi-PET, which looks at tumor stroma instead of the tumor cells themselves. This project will determine the performance of FAPi-PET for prostate cancer detection and prognosis, and will be used to launch the development of new FAP-targeting precision medicines
Understanding the Role of Androgen Signaling in Facilitating Immune Evasion in Advanced Prostate Cancer
What this means to patients: Dr. Chesner is investigating whether levels of MHC, which are proteins required for anti-tumor immune responses, are suppressed in prostate cancer via AR. This project will also reveal whether AR-targeted therapy may synergize with immunotherapy and could lead to new therapeutic strategies for patients with prostate cancer.
Discovering Precision Oncology Approaches for CDK12-Deficient Prostate Cancer
What this means to patients: Dr. Chou is studying the biology of CDK12-mutated prostate cancers, a distinct molecular subtype of prostate cancer, which is seen in ~7% of mCRPC patients. This project will identify the impact of CDK12 mutations on the AR pathway, and identify new treatment targets for patients with this more aggressive subtype of prostate cancer.
Defining the Role of Natural Killer Cells in the Radiotherapy Treatment Response of Metastatic Prostate Cancer
What this means to patients: Dr. Foroutan is studying NK immune cell biology in patients treated with LuPSMA combined with checkpoint immunotherapy or PARP-inhibitors. This project may help to identify NK cell biomarkers that are predictive of response to therapy and potential targets that could be used for NK cell immunotherapy to increase the efficacy of therapy outcome in patients with poor clinical outcome.
A Multi-Center Study to Assess the Impact of MRI for Detection of Aggressive Prostate Cancer in Men on Active Surveillance
What this means to patients: Dr. Giganti is developing a new standardized mpMRI method (“PRECISE score”) for more accurate risk assessment and monitoring of disease progression in prostate cancer patients undergoing active surveillance. This will lead to reduced global incidence of advanced and potentially lethal prostate cancer.
Exploration of Metabolomics for the Prevention of Lethal Prostate Cancer
What this means to patients: Dr. Graff is profiling metabolite alterations in prostate cancer patients in order to develop a biomarker that can be used to identify which patients are at highest risk for developing lethal disease. This will enable more informed treatment decisions for patients and may be leveraged for efforts to develop new targeted treatments.
Investigating the Pathological Role of AZI1 RNA in TMPRSS2-ERG Gene Fusion Formation
What this means to patients: Dr. Gupta has discovered an RNA that may induce the gene fusions that drive the development of 50% of prostate cancer cases. This project will validate this phenomenon and describe its mechanisms, which may lead to new strategies to prevent the initiation of prostate cancer.
Improving Outcomes for PARP Inhibition Treatment in Men with Lethal BRCA2 Mutant Prostate Cancer by Targeting the Tumor Microenvironment
What this means to patients: Dr. Hepburn is studying mechanisms of PARP inhibitor resistance in BRCA2-mutated prostate cancer and identifying new combination treatment strategies that will lead to improved outcomes for these patients.
Developing a Novel ctDNA-Based Approach to Patient Risk Stratification and Treatment Selection in mCRPC: A Large Population-Based Cohort Study
What this means to patients: Dr. Khalaf is developing non-invasive, blood-based biomarker tests that evaluate circulating tumor DNA levels and tumor mutations to predict outcomes and identify optimal treatment strategies for patients. This project will greatly accelerate precision medicine and improve outcomes for patients with prostate cancer.
Using CDK4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy
What this means to patients: Dr. Koshkin will test the efficacy of a novel treatment strategy that uses a CDK4/6-inhibitor followed by PSMA-targeted radioligand therapy in patients with mCRPC, which may improve outcomes and treatment options in patients with advanced prostate cancer.
Targeting Fc Gamma Receptors with Stereotactic Radiation to Reprogram Myeloid-Derived Immune Cells in the Prostate Tumor Microenvironment
What this means to patients: Radiation therapy can sometimes activate anti-tumor immune responses, and strategies that boost this effect will improve treatment efficacy and outcomes for patients. Dr. Marciscano will explore whether targeting FcɣRs on myeloid cell is an effective strategy to enhance the immune response to SBRT in men with prostate cancer.
Uncovering Lineage Plasticity in the Context of Specific Genomic Alterations in High Risk Prostate Cancer
What this means to patients: Dr. Nappi is investigating mechanisms of treatment resistance and response in patients with high-risk localized prostate cancer in a neoadjuvant precision medicine clinical trial. This study will uncover mechanisms associated with lineage plasticity and early signatures of treatment resistance, enabling refinement of future precision medicine approaches.
Biomarker-Based Approaches to Predict Fracture Risk among Men with Metastatic Hormone-Sensitive Prostate Cancer
What this means to patients: Dr. Parikh is developing new clinical biomarker tests that can identify which patients undergoing hormonal therapy are at risk for developing bone fractures, and should be prescribed early bone maintenance therapies. This will significantly improve quality-of-life for patients with advanced prostate cancer, starting with the Veteran population.
Interrupting the Aberrant Cancer Development Sequence in Prostate Cancer Progression
What this means to patients: Dr. Park will identify the essential genetic/molecular switches that control progression of prostate cancer into NEPC and enable NEPC to grow rapidly, which may represent new therapeutic targets for preventing or reversing NEPC development.
Metabolic Adaptations to Androgen Receptor Blockade and the Prostate Cancer Transcriptome.
What this means to patients: Dr. Paschalis is studying a novel environmental metabolic sensing pathway that may drive CRPC by altering expression levels of AR-V7. This project will determine the mechanisms of this pathway and validate the potential for targeting this pathway as a new treatment strategy in CRPC.
Molecular Pathology-Artificial Intelligence Approach to Therapy Response Prediction for Castration Resistant Prostate Cancer
What this means to patients: Dr. Antonio Rodriguez-Calero is developing a new artificial intelligence-based classification system for mCRPC based on molecular, pathology, and clinical data that will improve precision medicine treatment selection for patients with advanced prostate cancer.
Phase II Biomarker Study of Advanced Diffusion MRI in High-Risk, Localized Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy
What this means to patients: Dr. Seibert is developing a new MRI scan technique that will help to identify patients with high-risk localized prostate cancer who will vs. will not be cured by ADT + radiation therapy. This will enable clinicians to identify which patients should have additional therapy before waiting for recurrence to become apparent, and will lead to improved outcomes for patients with high-risk prostate cancer.
Integrated Single-Cell Analysis of Mechanisms of Therapeutic Resistance in Prostate Cancer Patients
What this means to patients: Dr. Tewari is investigating molecular mechanisms and biomarkers of response vs. resistance to intense anti-androgen neoadjuvant therapy, radiopharmaceuticals, and other treatments. This will result in improved selection of patients who will benefit from these treatments and potentially inform drug development efforts to improve the chance of cure for patients with prostate cancer.
Biochemical, Structural and Molecular Dissection of Androgen Receptor Transcriptional Activity
What this means to patients: Dr. Wasmuth will identify the precise regions of the AR that regulate its oncogenic activities and reveal novel strategies for developing new drugs to target this critical prostate cancer driver.
Studying the Mechanisms of Lineage Plasticity in Prostate Cancer
What this means to patients: Dr. Zaidi is studying the biology of lineage plasticity, a mechanism that drives development of an aggressive form of CRPC. These findings will uncover new therapeutic targets for drug development for this currently lethal prostate cancer subtype.
Investigating Cell of Origin and Molecular Mechanisms of Lineage Plasticity in Neuroendocrine Prostate Cancer
What this means to patients: Dr. Zhao is investigating the molecular drivers and role of neutrophils in lineage plasticity, a major form of treatment resistance in patients with mCRPC. This will lead to new understandings and identify promising new therapeutic strategies for patients with this highly aggressive form of prostate cancer.
- zosia bluszcz
- Posty: 11409
- Rejestracja: 13 cze 2009, 02:06
- Blog: Wyświetl blog (0)
Posty: 2
• Strona 1 z 1
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 14 gości
